Bristol Myers Squibb reported mixed results for admilparant in idiopathic pulmonary fibrosis, with only the lower tested dose meeting the trial’s main objective. Analysts raised questions about the program’s prospects given the lack of clear performance across doses. The disclosure keeps IPF as a high-stakes area where dose–response interpretation and endpoint robustness can materially change commercial expectations. It also reinforces that late-stage trial narratives are increasingly sensitive to dose-dependent efficacy and safety tradeoffs. For clinicians and pipeline planners, the immediate watch item is whether any subgroup signals or pharmacodynamic markers can support a narrower path forward—or whether the readout tightens the rationale to pivot.